(Q48238287)

English

The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.

scientific article published on 16 September 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25099027

The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25099027

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25099027

author name string

Yee Chao

1

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25099027

Young-Hwa Chung

2

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25099027

Guohong Han

3

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25099027

Jijin Yang

5

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25099027

Jianhua Wang

6

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25099027

Guo-Liang Shao

7

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25099027

Byung Ik Kim

8

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25099027

Teng-Yu Lee

9

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25099027

language of work or name

0 references

publication date

16 September 2014

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25099027

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25099027

136

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25099027

6

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25099027

1458-1467

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25099027

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

Management of hepatocellular carcinoma: An update

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009).

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

[Practice guidelines for management of hepatocellular carcinoma 2009].

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

Transcatheter arterial chemoembolization (TACE) with lipiodol to treat hepatocellular carcinoma: survey results from the TACE study group of Japan

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

BAY 43-9006: preclinical data

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

BAY 43-9006 inhibition of oncogenic RET mutants

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC).

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

Hepatocellular carcinoma in the Asia pacific region

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

Increased Expression of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29126

21 January 2018

Identifiers

10.1002/IJC.29126

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25099027

release_f3j6jjbvana6pfvjn7nyp4fbza

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25099027

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48238287&oldid=2135083678"